221 related articles for article (PubMed ID: 8676345)
21. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
[TBL] [Abstract][Full Text] [Related]
22. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
23. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Bagshawe KD
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
[TBL] [Abstract][Full Text] [Related]
24. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ
Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540
[TBL] [Abstract][Full Text] [Related]
25. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
[TBL] [Abstract][Full Text] [Related]
28. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
29. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
[TBL] [Abstract][Full Text] [Related]
30. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
31. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
Capucha V; Mendes E; Francisco AP; Perry MJ
Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
[TBL] [Abstract][Full Text] [Related]
32. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
[TBL] [Abstract][Full Text] [Related]
33. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
[TBL] [Abstract][Full Text] [Related]
34. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
35. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
38. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.
Marais R; Spooner RA; Stribbling SM; Light Y; Martin J; Springer CJ
Nat Biotechnol; 1997 Dec; 15(13):1373-7. PubMed ID: 9415889
[TBL] [Abstract][Full Text] [Related]
39. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
[TBL] [Abstract][Full Text] [Related]
40. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
